ERBB2 and breast cancer: According to the latest recommendation, patients with BC in which HER2 immunohistochemistry (IHC) 3+ or IHC 2+/fluorescence in situ hybridization (FISH) results are amplified are considered to be HER2 positive and eligible for several therapies that disrupt HER2 signaling pathways (Wolff et al., 2023).